United States (US)

TL1A (Active) recombinant protein

Cat No. GTX65483

Application ELISA, Functional Assay, Apuri, Blocking
Reactivity Human
Species Human

Application Note

The ED50 as determined by the dose-dependent inhibition of the proliferation of HUVEC is <5 ug/ml.

Calculated MW

21.8 kDa. ( Note )


Lyophilized powder


0.5 M NaCl, 50 mM Tris-HCl, pH 7.5.


Reconstitute in water to a concentration of 0.1–1.0 mg/ml. This solution can then be diluted into other aqueous buffers. Reconstitute in ddH2O. Store at -20ºC. Product is stable for at least 12 months.

Antigen Species


Expression System

E. coli


Purity was assessed by SDS-PAGE (≥95%) and by HPLC (≥95%).


For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.


TL1, TL1A, MGC129935., Tumor necrosis factor ligand superfamily member 15, TNFSF-15, TL-1, MGC129934, VEGI-192, TNF ligandrelated molecule 1, VEGI, TNF ligandrelated molecule1, VEGI192, Tumor necrosis factor ligand superfamily member15, TNFSF15, TNF ligand-related molecule 1, VEGI192A, TL 1, TNFSF 15, VEGI 192, TNF ligand related molecule 1


VEGI (Vascular Endothelial Growth Inhibitor) is a member of the tumor necrosis factor family. VEGI is predominantly an endothelial cell-specific gene, and recombinant VEGI is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. VEGI exerts two activities of endothelial cells: early Gl arrest of G0/G1-cells responding to growth stimuli, and programmed cell death. VEGI is also able to regulate the expression of several important genes involved in angiogenesis. Human VEGF is a 21.8 kDa homodimeric protein consisting of 192 amino acid polypeptide chains.

Research Area

Package List Price ($)
$ 339